SEC Tracker
Get the app

LENZ Therapeutics LENZ

LENZ Therapeutics Therapeutics cuts staff by 75%

Item 2.02 Reports results, Item 2.05 Exit or restructuring costs, Item 5.02 Executive or director change

Form
8-K
Filed
Importance
Major
  1. Reorganization includes 75% headcount reduction to 40 employees
  2. Estimates $5M in non-recurring charges for reorganization
  3. CEO Evert Schimmelpennink to resign on Dec 1, 2026
  4. Separation benefits include $731,400 cash and health coverage

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when LENZ Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2836) and public float $300M to $2B, nearest public float first, as each company reports it on its annual report cover.

  1. ImmunityBio IBRX public float $690M, Jun 30, 2025
  2. Vir Biotechnology VIR public float $689M, Jun 30, 2025
  3. Anavex Life Sciences AVXL public float $708M, Mar 31, 2025, over 18 months old
  4. Relay Therapeutics RLAY public float $586M, Jun 30, 2025
  5. Ginkgo Bioworks Holdings DNA public float $553M, Jun 28, 2025